Pasithea Therapeutics (KTTA) EBIT (2021 - 2026)
Pasithea Therapeutics recorded quarterly EBIT of -$4.9 million in Q1 2026, up 52.45% quarter-over-quarter from -$10.3 million in Q4 2025, and down 32.51% year-over-year from -$7.2 million in Q1 2025.
Pasithea Therapeutics' EBIT history runs 6 years deep, the most recent figure standing at -$4.9 million for Q1 2026.
- In Q1 2026, EBIT fell 32.51% year-over-year to -$4.9 million; the TTM figure through Mar 2026 stood at -$22.1 million (down 58.78% YoY), while the FY2025 annual figure was -$20.9 million, down 46.37% from the prior year.
- EBIT came in at -$4.9 million for Q1 2026 at Pasithea Therapeutics, up from -$10.3 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$2.4 million in Q1 2022 to a low of -$10.3 million in Q4 2025.
- A 5-year average of -$4.1 million and a median of -$3.8 million in 2025 frame the typical range for EBIT.
- Across the five-year window, EBIT slumped 337.5% in 2022 and jumped 36.69% in 2024, its largest moves.
- Pasithea Therapeutics' EBIT stood at -$4.0 million in 2022, then fell by 27.36% to -$5.1 million in 2023, then surged by 36.69% to -$3.3 million in 2024, then tumbled by 214.65% to -$10.3 million in 2025, then surged by 52.45% to -$4.9 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$4.9 million, -$10.3 million, and -$3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -4.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.88 Mn |
| Dec 31, 2025 | -10.26 Mn |
| Sep 30, 2025 | -3.11 Mn |
| Jun 30, 2025 | -3.81 Mn |
| Mar 31, 2025 | -3.68 Mn |
| Dec 31, 2024 | -3.26 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -3.95 Mn |
| Mar 31, 2024 | -4.04 Mn |
| Dec 31, 2023 | -5.15 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | -3.83 Mn |
| Mar 31, 2023 | -3.21 Mn |
| Dec 31, 2022 | -4.04 Mn |
| Sep 30, 2022 | -3.86 Mn |
| Jun 30, 2022 | -2.61 Mn |
| Mar 31, 2022 | -2.40 Mn |
| Dec 31, 2021 | -1.96 Mn |
| Sep 30, 2021 | -1.27 Mn |
| Jun 30, 2021 | -727,947.00 |
| Mar 31, 2021 | -549,609.00 |